ANTOINE HOLLEBECQUE ET AL: "A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours", EUROPEAN JOURNAL OF CANCER, vol. 50, no. 5, 20 January 2014 (2014-01-20), pages 876-884, XP055313714, AMSTERDAM, NL ISSN: 0959-8049, DOI: 10.1016/j.ejca.2013.12.006 (B1)

HUA ZHONG ET AL: "Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical Models", PLOS ONE, vol. 8, no. 10, 9 October 2013 (2013-10-09), page e77243, XP055313720, DOI: 10.1371/journal.pone.0077243 (B1)

WO-A1-2015/121657 (B1)

LEHANG LIN ET AL: "Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474)", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 44, 2 December 2013 (2013-12-02), pages 557-562, XP055313636, GR ISSN: 1019-6439, DOI: 10.3892/ijo.2013.2205 (B1)

WO-A1-2011/021038 (B1)

JIANGCHUAN TAO: "Combined treatment of BTK and PI3K inhibitors synergistically disrupts BCR-signaling, overcomes microenviroment-mediated survival and drug resistance in mantle cell lymphoma", AACR ANNUAL MEETING 2013, 10 April 2013 (2013-04-10), pages 1-2, XP055129363, (B1)